Gene2Cure Foundation and Viralgen collaborate to advance a portfolio of gene therapy programs for rare and ultra-rare genetic conditions
(Adnkronos) - Collaboration brings together Gene2Cure's portfolio development capabilities and Viralgen's proprietary Aava™ platform to support the efficient progression of programs for rare and ultra-rare genetic conditions toward the clinic.